Clinical Trial Update: Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial investigated combining nivolumab with chemoradiotherapy while omitting cisplatin in nasopharyngeal carcinoma; the study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED